Valion Bio announced that the U.S. Department of War's AFRRI and NIAID have finalized a survival efficacy protocol to test Entolimod, its lead drug candidate for Gastrointestinal Acute Radiation Syndrome (GI-ARS). This protocol uses a validated animal model compliant with FDA's Animal Rule, enabling drug approval based on animal studies when human trials are not feasible. Entolimod, a TLR5 agonist, shows promise as the first treatment for GI-ARS, a currently untreated and deadly condition, representing a significant commercial opportunity in the growing radiation countermeasures market. The company aims to generate critical data to support FDA approval and address a major unmet medical need driven by government emergency preparedness demands.
Jyske Realkredit A/S announced fixed coupon rates for several bond series effective from July 1 to September 30, 2026. The rates range from 2.31% to 2.92% per annum depending on the bond series. This update informs investors about the expected return...
Jyske Realkredit A/S announced the fixed coupon interest rates for several bond series effective from July 1, 2026, to September 30, 2026. The rates range from 2.31% to 2.92% per annum depending on the bond series. This update informs investors about...
Nyrstar NV released a legal opinion addressing the impact of its potential dissolution and liquidation on ongoing criminal cases and its ability to pursue claims against responsible third parties. This follows a notice from the FSMA and aims to clari...
Nyrstar NV has published a legal opinion from external lawyers regarding the impact of a potential company dissolution and liquidation on an ongoing criminal procedure and the company's ability to protect its rights by possibly filing claims against ...
Oblenio Bio secured $62 million in a Series B funding round led by Pfizer Ventures to support clinical development of LBL-051, a tri-specific T-cell engager targeting autoimmune diseases. LBL-051 aims to reset the immune system by depleting B-cells a...
